转移灶导向治疗联合标准治疗对比标准治疗用于寡转移前列腺癌:WOLVERINE系统评价与个体患者数据Meta分析
MDT显著改善无进展生存、影像学无进展生存和去势抵抗无生存,总生存获益未达统计学显著。
核心结论
- WOLVERINE显示MDT用于寡转移前列腺癌可改善无进展生存、影像学无进展生存和去势抵抗无生存。
- 总生存获益未达统计学显著,需进一步研究。
研究设计与样本
- 采用Cochrane偏倚风险评估2.0版,主要分析采用随机效应模型(试验水平)和按试验分层的患者水平分析。
临床怎么用
- 对于寡转移(最多5处转移)前列腺癌患者,MDT联合标准治疗可作为改善疾病控制的选择。
- 总生存获益未证实,临床决策需结合患者具体情况并关注后续研究。
局限性
- 纳入研究均为2期试验,样本量有限(主要分析472例)。
- 总生存分析未达统计学显著,需更长随访或更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oligometastatic disease represents the proximal end of a metastatic spectrum. Metastasis-directed therapy (MDT) is increasingly used to treat oligometastatic disease despite the absence of level 1 evidence. We amalgamated individual patient data across trials to evaluate the effectiveness of MDT for oligometastatic prostate cancer. METHODS: We conducted a systematic review and individual patient data meta-analysis. We systematically searched Embase, PubMed, CENTRAL, MEDLINE, and ClinicalTrials.gov to identify randomised trials of MDT enrolling patients with oligometastatic prostate cancer. Inclusion criteria were published randomised prospective trials enrolling patients with oligometastatic (up to five metastases) prostate cancer, in which investigators recorded sufficient data to evaluate progression-free survival and overall survival. This systematic review was conducted from database creation to Nov 3, 2023, and was updated on May 4, 2025. Data appraisal was conducted using Covidence with two investigators (CT and ADS) performing independent screens. Studies were evaluated using the Cochrane Collaboration's risk-of-bias assessment (version 2.0). Individual patient data were provided by investigators. Coprimary endpoints were progression-free survival and overall survival. Secondary endpoints were radiographic progression-free survival and castration resistance-free survival. The primary analysis was conducted in the subset of studies in which patients were randomly assigned to MDT plus standard of care (SOC) versus SOC. The primary analysis included a trial-level analysis using a random effects model and a patient-level analysis stratifying by trial. This meta-analysis is registered with PROSPERO (CRD42023479078). FINDINGS: Of 2975 studies identified for screening, seven phase 2 studies randomly assigning 574 men were included. Six trials randomly assigning 472 patients to MDT plus SOC (n=248) versus SOC (n=224) were used to evaluate MDT and had a median follow-up time of 40·7 months (IQR 25·6-53·7). MDT was associated with improved progression-free survival (trial-level hazard ratio [HR] 0·44, [95% CI 0·35-0·56], p<0·0001; patient-level HR 0·45 [0·35-0·57], p<0·0001), radiographic progression-free survival (trial-level HR 0·60 [0·42-0·85], p=0·0039; patient-level HR 0·59 [0·46-0·76], p<0·0001), and castration resistance-free survival (trial-level HR 0·58 [95% CI 0·37-0·92], p=0·019; patient-level HR 0·58 [95% CI 0·37-0·91], p=0·017). The association between MDT and overall survival showed an HR of 0·63 (95% CI 0·39-1·00, p=0·051) in trial-level analyses and 0·64 (95% CI 0·40-1·01, p=0·057) in patient-level analyses. INTERPRETATION: WOLVERINE showed a benefit with MDT for oligometastatic prostate cancer in progression-free survival, radiological progression-free survival, and castration resistance-free survival. Overall survival benefit was not significant and further research is needed. FUNDING: Philanthropic gift and National Cancer Institute.
引用
- Tang C, Sherry AD, Hwang H, et al. Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration. Lancet Oncol. 2026. PMID: 41643695. doi:10.1016/S1470-2045(25)00658-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。